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Type 1 diabetes is a chronic autoimmune condition accounting for 5-10% of diabetes 
cases diagnosed worldwide1. Hypoglycaemia is common, limiting efforts to achieve tight 
glucose control, and linked to lower quality of life2 and increased mortality3. Insulin 
analogues, structured education, insulin pump therapy and continuous glucose monitoring 
have helped to decrease the burden of hypoglycaemia4,5 which is still considerable.  
Flash glucose monitoring, as reported by Bolinder et al in this issue of the Lancet6, is 
a novel unconventional glucose monitoring tool.  Build on well-tested wired-enzyme glucose-
oxidase sensing approach originally developed for continuous glucose monitoring, utilising 
tight quality-control manufacturing processes and underpinned by physiological research7, 
flash glucose monitoring offers a two-week, externally-worn glucose sensor displaying 
present, 8-hour historic, and trend glucose data when scanned by the user using a near-field 
scanner8 in a similar fashion as when using a contactless payment card. The device does 
not provide low or high glucose alarms but this reduction in functionality has surprisingly little 
effect on user acceptability. The unique benefit is that the sensor is factory calibrated; no 
calibrations are needed and the sensor provides glucose values for non-adjunctive diabetes 
treatment decisions. In a randomised controlled parallel design multicentre multinational 
study, well-controlled type 1 diabetes adults with mean HbA1c 6.7% used flash glucose 
monitoring over 6 months with a key finding of reduced time spent hypoglycaemic below 
3.9mmol/l by mean 38% compared to conventional self-monitoring of blood glucose. 
Applying flash glucose monitoring, capillary glucose monitoring frequency dropped to mean 
one every two days. Time spent hyperglycaemic above 13.3mmol/l was reduced, mean 
glucose and HbA1c were unchanged, glycaemic variability was reduced and diabetes-
related quality of life improved as well as user reported treatment satisfaction.  
What could explain the benefits reported? Flash glucose monitoring, in the same 
manner as continuous glucose monitoring, is a behavioural modification tool. Users need to 
respond to glucose measurements by adjusting insulin delivery, modifying eating habits and 
exercise management. Such a behaviour adaptation occurred within 10 days of starting to 
use flash glucose monitoring, as hypoglycaemia was reduced and remained stable 
throughout. The number of scans started at mean 18 per day and reduced slightly to mean 
15 per day 3 months later. This frequency was much higher compared to mean 6 capillary 
glucose measurements applied in the comparator self-blood glucose monitoring group. The 
convenience of inspecting glucose levels in a “flash”, on average once an hour during the 
daytime, appears key but indicates unrelenting round-the-clock attention to diabetes self-
care to limit hypoglycaemia.  Visualisation of historical glucose data may have enhanced 
aspects of care and support provided by educators. The authors do not report on details of 
behavioural adaptations and therapy optimisations.  
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How do these findings impact clinical practice? Hypoglycaemia reduction was 
observed in both multiple daily injections and insulin pump users, suggesting that benefits 
can be accrued irrespective of insulin delivery methods used. Interestingly this reduction was 
comparable to studies using low glucose suspend insulin pump therapy9. The exclusion 
of sub-optimally controlled and hypoglycaemia unaware users limits the generalisability to 
wider populations of people with type 1 diabetes including youth. Adherence to flash glucose 
monitoring was high, which may be related to the convenience associated with its use.  This 
is line with our own personal experience in clinical practice, and many users appear willing to 
self-fund this technology. The non-adjunctive use to guide treatment decisions and 
insulin dosing is an important benefit, however training of users and healthcare providers is 
still needed to review and interpret sensor glucose values and trends appropriately.  
Flash glucose monitoring has the potential to enhance the management paradigm of 
type 1 diabetes care, empowering users’ informed decision-making whilst reducing burden 
associated with self-blood glucose monitoring. Amongst commonly reported barriers to wider 
adoption of continuous glucose monitoring are the need for calibrations, alarm fatigue, 
frequent sensor changes and cost10 which may be alleviated by flash glucose monitoring. 
Well-conducted studies in more generalizable clinical population in which aspects of 
behaviour modification induced by use of this technology can be ascertained are needed to 
provide further guidance to health-care providers and funders, as well as comparisons with 
emerging automated insulin delivery systems11. 
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